News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Genflow Biosciences advances three major programs in fight against ageing diseases

Genflow Biosciences PLC

Genflow Biosciences PLC CE Dr Eric Leire tells Proactive's Stephen Gunnion the company had a successful year in 2023, allowing it to expand its research and development pipeline. Leire highlighted three main programs during an interview. The first focuses on MASH (Metabolic Dysfunction-Associated Steatohepatitis), soon progressing to clinical trials, indicating a strong move towards addressing liver diseases. The second program deals with Werner Syndrome, a progeria-related condition, where Genflow is innovating with synthetic organoids to mimic human organ function for better clinical trial predictions. The third program targets sarcopenia in collaboration with Revatis SA, aiming to combat muscle loss associated with ageing. The company has also engaged with regulatory agencies in Europe and the US, receiving positive feedback on its approach, particularly with its MASH program. It is awaiting further feedback from the FDA to decide the trial's location. In addition to a recent £715,000 fundraise, Genflow's financial strategy relies heavily on grants, with recent significant funding from the Wallonia Region in Belgium, which Leire believes positions it well to continue its work without heavy reliance on venture capital. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 09, 2024 07:37 AM Eastern Daylight Time

Video
Article thumbnail News Release

Cloud DX secures 4th Provincial Health contract for remote patient monitoring

Cloud DX

Robert Kaul, CEO of Cloud DX, discussed with Steve Darling from Proactive the new Remote Patient Monitoring Agreement for Cloud DX RPM Services, which has been secured with a Canadian Provincial Health Authority. This agreement expands Cloud DX's provision of Connected Health remote patient monitoring products and services across Canada, now including contracts with Alberta, Yukon, Prince Edward Island, and a Master Services Agreement with Mohawk Medbuy—the country's largest hospital procurement agency. Kaul shared with Proactive that the contract spans 36 months and includes options for two 12-month extensions. Each subscription under these contracts is projected to average $1,520 CAD annually, covering the costs associated with the Connected Health Kit, which includes patient-prescribed hardware, software, and connectivity solutions. Over the four months leading up to April 30, 2024, Cloud DX has announced a significant growth milestone, securing 26 new contracts. These agreements span across hospitals, paramedic services, U.S. clinics, and include two Canadian provinces, marking a significant inflection point in the company’s expansion and presence in the healthcare industry. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 08, 2024 02:48 PM Eastern Daylight Time

Video
Article thumbnail News Release

Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of drugs for treating and preventing hypercytokinemia (cytokine storms) in patients triggered by an immune response, applicable across multiple disease indications. The granted patent further solidifies Poolbeg Pharma's robust intellectual property portfolio for POLB 001, potentially increasing the asset's value and making it more attractive to potential partners. McEvoy highlighted the company's ongoing efforts to strengthen and expand their IP portfolio, noting existing patents covering p38 MAP kinase inhibitors for influenza treatment and hypercytokinemia. Additional patents have been filed, particularly focusing on cancer immunotherapy applications of POLB 001. The company has also applied for patents concerning dosage regimens based on results from their recent LPs trial, aiming to protect innovations and maintain a competitive edge in the pharmaceutical market. This strategic IP protection is crucial for safeguarding the company's products and ensuring shareholder value, particularly as they seek partnerships to further develop POLB 001. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 08, 2024 08:32 AM Eastern Daylight Time

Video
Article thumbnail News Release

Creo Medical honoured with King's Award for Enterprise in Innovation

Creo Medical Group PLC

Creo Medical Group PLC (AIM: CREO) CEO Craig Gulliford joins Proactive's Stephen Gunnion with the news that the company has been recognised with the King's Award for Enterprise in Innovation, an accolade honouring innovative UK companies for their impact in their respective sectors. The award highlights Creo's influence on patient outcomes through their advanced medical technologies. Gulliford emphasised the rare honour, noting that among over five million companies in the UK, only 59 received this award this year. The company leverages a unique combination of bipolar radiofrequency energy with microwave energy, focusing on miniaturising surgical procedures. This innovation has led to significant advancements in treatment effectiveness and cost-efficiency, particularly noted in a recent NHS case study that showcased substantial economic benefits, including a reduction in theatre costs and patient hospital stays. This recognition allows Creo Medical Group to join a select group of internationally recognised brands, enhancing their credibility and market presence. Gulliford expressed pride in the team's achievement and optimism about future innovations, particularly in addressing complex medical conditions like lung cancer. The award not only validates past efforts but also sets a high standard for the company's ongoing commitment to healthcare innovation. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 08, 2024 07:50 AM Eastern Daylight Time

Video
Article thumbnail News Release

Shedding Light on Cystic Fibrosis Awareness Month

YourUpdateTV

Cystic fibrosis (CF) is a rare, progressive, and genetic disease that currently affects about 40,000 people in the United States. CF is the result of a defective gene, inherited from each parent, and the disease can impact people of all races and ethnicities. Recently, KC White, Board Chair of the Cystic Fibrosis Foundation, participated in a nationwide satellite media tour to discuss the disease, her personal journey, and how the Foundation is helping progress care and treatment options. A video accompanying this announcement is available at: https://youtu.be/8wj8u0JEqLU CF is a life-shortening disease that prevents our bodies from clearing mucus. This can lead to lung infections, poor nutrition, lung disease, and a host of unique challenges that can impact every aspect of a person’s life. When it was first discovered, it was considered a fatal pediatric disease. But due to transformative advancements in treatments and high-quality care, the life-expectancy for someone born with CF today is 56. While that number is climbing there is still a long way to go and unfortunately, not all people with CF equally benefit from this progress. KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood and is the first person with CF to serve as board chair. When she was diagnosed, she wasn’t expected to live past high school age, but her family refused to accept that fate, which prompted their dedication to the Foundation’s work. Because of recent treatments known as modulators, about 90% of the CF population (including KC) experienced an incredible transformation in their health. With this though, comes navigating unplanned challenges including careers, finances, family, and more. In addition to fueling the research, particularly in genetic therapies, that will lead to transformative treatments for the entire CF population, the CF Foundation works to support the CF community in all aspects of their lives through support programs and fostering connection opportunities. Every May, the cystic fibrosis community comes together for CF Awareness Month to educate the public about the rare disease, share personal stories, and encourage people to get involved and unite behind a shared mission: finding a cure for all people with CF. The CF Foundation is committed to finding a cure and providing all people with CF the opportunity to lead long, fulfilling lives. The Foundation is aggressively funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. For more information, visit CFF.ORG/CFMONTH About KC White KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood, speaking at her first Foundation event when she was only 9 years old. She is the first person with CF to serve as board chair. White received her Master of Applied Positive Psychology from the University of Pennsylvania in 2022 and currently serves as an assistant instructor in the program. She is also the Head Varsity Women’s Lacrosse coach for the Chagrin Falls, Ohio, Tigers. She and her husband, Justin, have one son, Mac. About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is a donor-supported nonprofit organization leading the relentless pursuit of a cure for cystic fibrosis. The Foundation is committed to providing all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. The organization supports and accredits a national network of over 130 CF care centers recognized by the National Institutes of Health as a model of care for a chronic disease. Also, the Foundation manages support programs and fosters connection opportunities for the CF community. Based in Bethesda, Md., the Foundation’s impact is made possible by the work of nearly 70 local chapters across the country. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 07, 2024 09:23 AM Eastern Daylight Time

Video
Article thumbnail News Release

5thScape to list its first game “MMA Cage Conquest” on Meta Store: Ultimate Virtual MMA Experience

Spark Metro PR

Mixed Martial Arts fans and enthusiasts, your virtual fighting dreams have arrived! 5th Scape delivers a transformative experience with "MMA Cage Conquest," stepping far beyond traditional fighting games into true sensory immersion. Step into the iconic MMA cage, feel the roar of the crowd and become the champion you always envisioned. The 5thScape Project is an ambitious venture that aims to create a comprehensive Virtual Reality ecosystem. In this VR ecosystem many developers, gamers and experts from various industries can collaborate. This is a VR gaming studio startup in which they focus on developing games, movies, animations etc. Apart from this, they are also planning to launch a special VR headset and a VR Chair which is an ergonomically perfect chair for long gaming sessions. Now, coming back to the game, - "MMA Cage Conquest" redefines virtual combat. Its skill-based system demands true martial arts strategy along with honed reflexes. Learn and master strikes like a real-life wrestling professional. It includes (not limited to) powerful grappling throws and the intricacies of ground control to secure your victories. Feel the impact of every blow, the thrill of a perfectly executed submission, and the tension of a match fought on the razor's edge. Training lies at the heart of "MMA Cage Conquest." This journey transcends button-mashing and enters the realm of personal development. Start as an eager underdog, mastering the fundamentals through rigorous simulations. Refine your striking, defense, and ground game, tracking your progression and building unshakeable confidence. With each session, you don't just play the game – you live the fight. MMA Cage Conquest is all set to make gaming experiences more vigorous and a powerhouse for the senses. Feel the rush in your bones as you climb the leaderboards, and establish yourself as the ultimate MMA cage conqueror. Ready to unleash your inner champion? " MMA Cage Conquest " will be available on the Meta platform. Submitted for listing on May 2, 2024, the developers await approval from Meta. Visit 5thscape.com for trailers, release updates, and the latest news on your journey to become the undisputed MMA Cage Conqueror. Contact Details 5th Scape 5thScape Team +1 302-597-6768 Team@5thscape.com Company Website https://5thscape.com

May 03, 2024 06:51 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

TOWER CAPITAL GROUP SPONSORS A GLOBAL INVESTMENT CONSORTIUM

TOWER CAPITAL GROUP

TOWER CAPITAL GROUP, market maker of Generational Health, defines the trillion dollar category as pivotal to evolutionary capacity, country competitiveness, and global health. In a recent publication TOWER reveals that a critical lever for Generational Health is Women’s Health. TOWER states that funding women’s health innovation is a requirement for Generational Health and has committed to support this effort at a global scale. In demonstration of this commitment, TOWER expands its relationship with the Centre for Health and Healthcare at The World Economic Forum, and is the lead champion and sponsor of a first-in-kind global women’s health investment consortium. The Consortium, ”Global Women’s Health Responsible Investment Consortium” is designed to serve the global need for innovation in women’s health. Not only to be a channel of investment, but responsible and sustainable funding for the category. The Consortium serves to: Unite Global Investors with Global Innovators for Women’s Health Outcomes Accelerate and Measure Commitments to Funding and Secure Matching Commitment to select Innovators Leverage The World Economic Forum and Global Alliance for Women’s Health Platform to Curate Investment Outcomes Amplify Tower Capital’s Collective of ~1000+ Innovators Open the Aperture of Women’s Health Through the Lens of Generational Health “There is nothing more important than actualizing innovation and scientific breakthroughs for women, to ensure Generational Health.” Sanskriti Thakur, TOWER CAPITAL GROUP Founder and Chairwoman. “In collaboration with TOWER CAPITAL, we are delighted to launch the First Global Responsible Investment Consortium for Women’s Health. Together, let’s bridge the funding gap and unlock innovation for better health outcomes for all women.“ Shyam Bishen, Head, Centre for Health & Healthcare, The World Economic Forum. About TOWER: Operating across industries, regions and partners, TOWER CAPITAL GROUP and its affiliates deploy expertise and capital to uncover economic value, investment, and innovation within Generational Health and bring it to stakeholders across the globe. Generational Health are those effects passed on genetically, epigenetically, and environmentally, shaping humanity’s evolutionary curve. It represents a multi-trillion-dollar opportunity encompassing critical areas of community, environment, and women’s health. Visit www.towercapital.org for more information on Generational Health, the company, and its mission. Investor Inquiries: Sheri Bailey sheri@towercapital.org Contact Details For Media Inquiries please contact TOWER CAPITAL GROUP contact@towercapital.org Company Website https://towercapital.org/

May 01, 2024 12:00 PM Eastern Daylight Time

Article thumbnail News Release

Nevis Brands Expands Major Distribution with Exclusive Licensing Agreement in Mississippi

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to announce the company has announced a significant expansion in Major's distribution through an exclusive licensing agreement with Stash House for production and distribution in Mississippi. Under this agreement, Stash House will have exclusive rights to produce and distribute the full lineup of Major products in the state. The Major lineup includes dose-able 100mg THC beverages available in flavors such as Blueberry, Fruit Punch, and Blackberry Lemonade. Known for delivering the effects of cannabis within a short timeframe of 10-20 minutes after consumption, Major has gained popularity since its initial launch in Washington State in 2019, with over 5 million bottles sold to date. Kueber highlighted Mississippi's recent legalization of cannabis for medical use in January 2023, which has led to the licensing of over 400 dispensaries in the state. This agreement marks Major's entry into its 10th state for production, further expanding its reach across the United States. Currently available in Washington, Oregon, Arizona, Ohio, Colorado, Nevada, California, and Missouri, Major is also preparing for production in Michigan, signaling the brand's continued growth and market penetration. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 30, 2024 12:12 PM Eastern Daylight Time

Video
Article thumbnail News Release

Cloud DX Reports Significant Revenue and Profit Growth in 2023

Cloud DX

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to discuss the company's impressive performance in its 2023 full-year results. Notably, Cloud DX reported a substantial 55.4% increase in revenue, reaching $1.8 million. A key driver of this growth was the remarkable surge in subscription revenue, which soared by nearly 70%, surpassing the overall revenue increase. This shift towards subscription revenue, characterized by high margins exceeding 90%, has significantly bolstered profitability, with gross profit doubling to $1.2 million, reflecting a remarkable 112% increase. The company's stellar performance is further underscored by its operational efficiency, as evidenced by a noteworthy $1.3 million reduction in operating expenses. This reduction was achieved through strategic staff cost management, executed without compromising on customer service quality. As a result, Cloud DX achieved a more than 20% decrease in operating loss, setting a positive trajectory towards profitability and positive cash flow in the coming quarters. Looking ahead, Cloud DX is well positioned to solidify its presence in the remote patient monitoring market in Canada. The company boasts the largest share of provincial contracts and maintains robust partnerships with major industry players such as Medtronic and Teladoc Health. Moreover, Cloud DX's successful early conversion of convertible debt at a premium underscores its strong financial management and commitment to enhancing shareholder value. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 30, 2024 12:04 PM Eastern Daylight Time

Video
1 23456 ... 121